Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) — Market Cap & Net Worth
Market Cap & Net Worth: Bicara Therapeutics Inc. Common Stock (BCAX)
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) has a market capitalization of $1.49 Billion ($1.49 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7266 globally and #2217 in its home market, demonstrating a -4.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bicara Therapeutics Inc. Common Stock's stock price $22.59 by its total outstanding shares 66172934 (66.17 Million). Also see BCAX asset base for a full breakdown of the balance sheet.
Bicara Therapeutics Inc. Common Stock Market Cap History: 2024 to 2026
Bicara Therapeutics Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $1.15 Billion to $1.49 Billion (11.94% CAGR). Also see cash efficiency ratio of Bicara Therapeutics Inc. Common Stock for how efficiently the company converts equity into cash flow.
Index Memberships
Bicara Therapeutics Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.06% | #212 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #814 of 3165 |
Weight: Bicara Therapeutics Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bicara Therapeutics Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bicara Therapeutics Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Bicara Therapeutics Inc. Common Stock stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BCAX by Market Capitalization
Companies near Bicara Therapeutics Inc. Common Stock in the global market cap rankings as of September 18, 2026. Review BCAX tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bicara Therapeutics Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Bicara Therapeutics Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Bicara Therapeutics Inc. Common Stock's market cap moved from $1.15 Billion to $ 1.49 Billion, with a yearly change of 11.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.49 Billion | +34.22% |
| 2025 | $1.11 Billion | -3.39% |
| 2024 | $1.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Bicara Therapeutics Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Billion USD |
| MoneyControl | $1.49 Billion USD |
| MarketWatch | $1.49 Billion USD |
| marketcap.company | $1.49 Billion USD |
| Reuters | $1.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more